Day: August 26, 2021

HONKARAKENNE OYJ                   HALF YEAR FINANCIAL REPORT 26 August 2021   at 9:00 a.m. HONKARAKENNE OYJ HALF YEAR FINANCIAL REPORT, 1 JANUARY – 30 JUNE 2021 SIGNIFICANT INCREASES IN NET SALES AND OPERATING PROFIT, ORDER BOOK HISTORICALLY LARGE Net sales for the first half of 2021 increased by 31 per cent to EUR 29.6 million (H1 2020: EUR 22.6 million). Both operating profit and profit before taxes improved significantly from the previous year. Operating profit increased by 70 per cent to EUR 1.7 million (EUR 1.0 million). Profit before taxes increased by 69 per cent to EUR 1.7 million (EUR 1.0 million). January–June 2021Honkarakenne Group’s net sales for the January–June period were EUR 29.6 million (H1 2020: EUR 22.6 million). Net sales increased by 31 per cent compared to the corresponding period of the previous year. The operating...

PRESS RELEASE August 26, 2021 Three Months Ended June 30, 2021 (2020)Revenue was SEK 1.9 M (2.0 M)Operating loss was SEK -103.6 M (-26.0 M)Net profit/loss was SEK -103.9 M (-23.9 M)Basic loss per share was SEK -1.67 (-0.81)Diluted loss per share was SEK -1.67 (-0.81) Six Months Ended June 30, 2021 (2020)Revenue was SEK 5.3 M (4.4 M)Operating loss was SEK -197.7 M (-53.5 M)Net profit (loss) was SEK -187.3 M (19.3 M)Basic earnings (loss) per share was SEK -3.00 (0.65)Diluted earnings (loss) per share was SEK -3.00 (0.65) Business highlights in Q2 2021Saniona achieved a key milestone with the initiation of a Phase 1 clinical trial of SAN711, an ion channel modulator that may be applicable in the treatment of rare neuropathic disorders. This is the first wholly-owned asset from Saniona’s proprietary ion channel drug discovery engine...

For the first half of 2021, Vow ASA (“Vow” or the “Company”) reported NOK 201 million in revenues and a steady 10 per cent EBITDA margin before non-recurring items. The order backlog has climbed to a new record at the time of reporting, NOK 1.1 billion in firm orders and another NOK 780 million in options. “The resilience of our Cruise Project business during the pandemic is one striking feature of this report. So far this year, our order intake from cruise customers amounts to NOK 200 million plus NOK 135 million in options. And now, as the cruise industry has begun taking ships back in operation, we expect that the market for our Aftersales segment will gradually recover,” said Henrik Badin, CEO of Vow. Total Vow revenues in the first six months this year were NOK 201 million, down NOK 47 million or 18 percent compared to the same period...

PRESS RELEASE – PARIS, 26/08/2021 FIRST-HALF 2021 RESULTSEXCELLENT FIRST-HALF 2021 RESULTSStrong growth in sales and earnings versus H1 2020 H1 2021 results return to pre-crisis levelVERY ROBUST FINANCIAL STRUCTURERecord level of liquidity for a mid-year and net debt at end-June at a historical lowGUIDANCE FOR THE GROUP REVISED UPWARDKEY FIGURES(€ million) H1 2020   H1 2021   Change   H1 2019   Change                   Sales 14,758   17,417   +18% a 17,446   0%Current operating profit/(loss) (132)   471   +€603m   453   +€18mCurrent operating margin -0.9%   2.7%   +3.6 pts   2.6%   +0.1 ptOperating profit/(loss) (176) b 551 c +€727m   495   +€56mNet profit/(loss) attributable to the Group (244)   408   +€652m   225   +€183m                   Net surplus cash (+)/net debt (-) (3,905)   (2,813)   +€1,092m   (6,205)   +€3,392m(a)...

Frontline Ltd. (the “Company” or “Frontline”), today reported unaudited results for the three and six months ended June 30, 2021: HighlightsNet loss of $26.6 million, or $0.13 per basic and diluted share for the second quarter of 2021. Adjusted net loss of $23.2 million, or $0.12 per basic and diluted share for the second quarter of 2021. Reported total operating revenues of $170.0 million for the second quarter of 2021. Reported spot TCEs for VLCCs, Suezmax tankers and LR2 tankers in the second quarter of 2021 were $15,000, $11,000 and $10,600 per day, respectively. For the third quarter of 2021, we estimate spot TCE on a load-to discharge basis of $14,000 contracted for 70% of vessel days for VLCCs, $9,800 contracted for 64% of vessel days for Suezmax tankers and $11,800 contracted for 63% of vessel days for LR2 tankers. We expect...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 SIX LISTING RULES Geneva, 26 August 2021 ENR RUSSIA INVEST SA ANNOUNCES 2021 HALF-YEAR RESULTS For the six months ended 30 June 2021 ENR Russia Invest SA (“ENR”) and its subsidiaries produced a consolidated net profit of CHF 2.94 million (consolidated net loss of CHF 4.58 million for the similar period in 2020) mainly due to higher valuations arising from ruble appreciation against the Swiss Franc. The consolidated equity increased to CHF 41.05 million (CHF 36.76 million at 31 December 2020). In the reporting period ENR sold shares and fixed income instruments for CHF 2.59 million. Proceeds were used for further investments in Kaluga Flower Holding LLC (ruble 90.4 million or CHF 1.08 million) in Russia, to reinvest in equities (CHF 0.67 million) and to increase cash on hand. At the flower growing...

PRESS RELEASE: REGULATED INFORMATION 26 August 2021, 07:00 CEST BIOCARTIS ANNOUNCES 2021 HALF–YEAR RESULTS ON 2 SEPTEMBER 2021 Mechelen, Belgium, 26 August 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today that it will report its 2021 half-year results and outlook for the remainder of the year on 2 September 2021 at 07:00 CEST. The Biocartis management team will host a conference call with live webcast presentation on the day of the results announcement, 2 September 2021 at 14:30h CEST / 13:30h BST (UK) / 08:30h EDT (US).The live webcast can be accessed here. If you would like to participate in the questions and answers session, please dial in 5-10 minutes prior to the start time using the numbers below and confirmation code 4866873. Dial-ins:Belgium,...

— Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage trials EMPATHY and ACTIV-3 Research & Development:Initiated two global Phase 2 and 3 trials of ensovibep (MP0420), to explore safety and efficacy in ambulatory patients with COVID-19 (EMPATHY) in collaboration with Novartis, and hospitalized patients (ACTIV-3) sponsored by the National Institutes of Health (NIH) Received FDA Fast Track designation for ensovibep for the treatment of COVID-19 in both hospitalized and ambulatory settings Initiated and fully enrolled Phase 2a single arm study of ensovibep in the Netherlands in patients with mildly symptomatic COVID-19, with data expected to be presented in a scientific conference in H2 2021 Reported that in vitro studies...